Second Supplemental Indenture - American Medical Systems, Inc.



 Exhibit 4.17 
 SECOND SUPPLEMENTAL INDENTURE 
 SECOND SUPPLEMENTAL
INDENTURE (this “Second Supplemental Indenture”), dated as of August 16, 2011, among American Medical Systems, Inc., a Delaware corporation (“AMS”), and Laserscope, a California corporation
(“Laserscope,” and, together with AMS, the “Successor Guarantors”), each a wholly-owned subsidiary of Endo Pharmaceuticals Holdings Inc. (or its permitted successor), a Delaware corporation (the
“Company”), the Company, the other Guarantors (as defined in the Indenture referred to herein) and Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”).

 W I T N E S S E T H 
 WHEREAS, the Company has heretofore executed and delivered to the Trustee an indenture, dated as of June 8, 2011, as supplemented by a first supplemental indenture dated as of June 17, 2011 (as
so supplemented, the “Indenture;” capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture), providing for the issuance of 7 1/4% Senior Notes due 2022 (the “Notes”);

 WHEREAS, on the date hereof (i) each of Thermatrx, Inc., a Delaware corporation and a wholly-owned subsidiary of
the Company, and Solarant Medical, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company, merged with and into AMS, a Guarantor under the Indenture (a “Predecessor Guarantor”), with AMS surviving such mergers,
and (ii) each of Laserscope International, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company, and InnovaQuartz Incorporated, an Arizona corporation and a wholly-owned subsidiary of the Company, merged with and into
Laserscope, a Guarantor under the Indenture (a “Predecessor Guarantor”), with Laserscope surviving such mergers; 
 WHEREAS, on the date hereof, each Successor Guarantor has executed and delivered a counterpart to the Registration Rights Agreement, evidencing its assumption of all obligations of its Predecessor
Guarantor under the Registration Rights Agreement; 
 WHEREAS, the Indenture provides that under certain circumstances each of
the Successor Guarantors shall execute and deliver to the Trustee a supplemental indenture pursuant to which each such Successor Guarantor shall unconditionally assume all of the obligations of its Predecessor Guarantor under the Indenture and such
Predecessor Guarantor’s Note Guarantee; and 
 WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee is
authorized to execute and deliver this Second Supplemental Indenture. 
 NOW, THEREFORE, in consideration of the foregoing and
for other good and valuable consideration, the receipt of which is hereby acknowledged, each Successor Guarantor and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 

1. CAPITALIZED TERMS. Capitalized terms used herein without definition shall have the meanings assigned to
them in the Indenture. 

  
 1 








 2. AGREEMENT TO ASSUME
OBLIGATIONS. Each Successor Guarantor hereby agrees to unconditionally assume all of the obligations of its Predecessor Guarantor under such Predecessor Guarantor’s Note Guarantee, the Indenture and the Registration Rights
Agreement. 
 3. NO RECOURSE AGAINST OTHERS. No director, officer,
employee, incorporator or stockholder of the Company or any Guarantor, as such, will have any liability for any obligations of the Company or the Guarantors under the Notes, this Indenture, the Note Guarantees or for any claim based on, in respect
of, or by reason of, such obligations or their creation. Each Holder of Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes. The waiver may not be effective
to waive liabilities under the federal securities laws. 
 4. NEW YORK LAW TO GOVERN; WAIVER OF JURY TRIAL. THIS SECOND
SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. THE COMPANY, THE TRUSTEE AND EACH OF THE GUARANTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY
AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS SECOND SUPPLEMENTAL INDENTURE OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 5. COUNTERPARTS. The parties may sign any number of copies of this Second Supplemental Indenture. Each signed copy (which may be provided via facsimile or other electronic transmission)
shall be an original, but all of them together represent the same agreement. 
 6. EFFECT OF
HEADINGS. The Section headings herein are for convenience only and shall not affect the construction hereof. 

7. THE TRUSTEE. The Trustee shall not be responsible in any manner whatsoever for or in respect of the
validity or sufficiency of this Second Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Successor Guarantors, the other Guarantors and the Company. 

  
 2 








 IN WITNESS WHEREOF, the parties hereto have caused this Second Supplemental Indenture to be
duly executed and attested, all as of the date first above written. 
  

					
	SUCCESSOR GUARANTORS:
	
	AMERICAN MEDICAL SYSTEMS, INC.
		
	By	 	 /s/ Caroline B. Manogue

	Name:	 	 Caroline B. Manogue

	Title:	 	 Executive Vice President,

		 	 Chief Legal Officer and Secretary

	
	LASERSCOPE
		
	By	 	 /s/ Caroline B. Manogue

	Name:	 	 Caroline B. Manogue

	Title:	 	 Executive Vice President,

		 	 Chief Legal Officer and Secretary

	
	COMPANY:
	
	ENDO PHARMACEUTICALS HOLDINGS INC.
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	Executive Vice President and
		 		 	Chief Financial Officer
	
	GUARANTORS:
	
	ENDO PHARMACEUTICALS INC.
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	 ENDO PHARMACEUTICALS SOLUTIONS
 INC.

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer










 
					
	ENDO PHARMACEUTICALS VALERA INC.
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	GENERICS INTERNATIONAL (US), INC.
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	GENERICS BIDCO I, LLC
		 	By GENERICS INTERNATIONAL (US),
		 	INC., its sole member
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	VINTAGE PHARMACEUTICALS, LLC
		 	By GENERICS INTERNATIONAL (US),
		 	INC., its sole member
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	LEDGEMONT ROYALTY SUB LLC
		 	By ENDO PHARMACEUTICALS
		 	SOLUTIONS INC., its sole member
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer










 
			
	 AMERICAN MEDICAL SYSTEMS
 HOLDINGS, INC.

		
	 By
	 	 /s/ Caroline B. Manogue

	 Name: Caroline B. Manogue

	 Title:   Executive Vice President,

	             Chief Legal Officer and
Secretary

	
	 AMS RESEARCH CORPORATION

		
	 By
	 	 /s/ Caroline B. Manogue

	 Name: Caroline B. Manogue

	 Title:   Executive Vice President,

            Chief Legal Officer and
Secretary


	
	 AMS SALES CORPORATION

		
	 By
	 	 /s/ Caroline B. Manogue

	 Name: Caroline B. Manogue

	 Title:   Executive Vice President,

            Chief Legal Officer and Secretary




  

			
	 PENWEST PHARMACEUTICALS CO.

		
	 By:
	 	 /s/ Alan G. Levin

		 	 Name: Alan G. Levin

		 	 Title:   Executive Vice President and

            Chief Financial
Officer










 
			
	 WELLS FARGO BANK, NATIONAL
ASSOCIATION,
 as Trustee

		
	 By:
	 	 /s/ Martin G. Reed

		 	 Name: Martin G. Reed

		 	 Title:   Vice President